Bank of America Boosts Phibro Animal Health (NASDAQ:PAHC) Price Target to $15.00

Phibro Animal Health (NASDAQ:PAHC) had its price target lifted by Bank of America from $13.00 to $15.00 in a research report report published on Friday, Benzinga reports. The firm currently has an underperform rating on the stock.

Separately, Barclays raised their price objective on Phibro Animal Health from $10.00 to $13.00 and gave the company an underweight rating in a research note on Friday, May 10th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Phibro Animal Health has a consensus rating of Hold and an average price target of $13.25.

Phibro Animal Health Trading Down 2.2 %

Shares of Phibro Animal Health stock opened at $21.00 on Friday. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.67 and a current ratio of 2.94. Phibro Animal Health has a 52 week low of $9.40 and a 52 week high of $22.31. The stock has a 50 day moving average price of $18.25 and a two-hundred day moving average price of $16.07. The stock has a market capitalization of $850.50 million, a PE ratio of 65.63, a price-to-earnings-growth ratio of 5.37 and a beta of 0.57.

Phibro Animal Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 25th. Investors of record on Wednesday, September 4th will be given a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, September 4th. This represents a $0.48 annualized dividend and a dividend yield of 2.29%. Phibro Animal Health’s payout ratio is 150.00%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Dana Investment Advisors Inc. boosted its position in shares of Phibro Animal Health by 17.2% during the second quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company’s stock valued at $8,619,000 after buying an additional 75,546 shares during the last quarter. Truist Financial Corp purchased a new position in shares of Phibro Animal Health during the second quarter valued at approximately $308,000. Brandes Investment Partners LP boosted its position in shares of Phibro Animal Health by 1.2% during the second quarter. Brandes Investment Partners LP now owns 2,405,629 shares of the company’s stock valued at $40,521,000 after buying an additional 29,071 shares during the last quarter. Algert Global LLC purchased a new position in shares of Phibro Animal Health during the second quarter valued at approximately $193,000. Finally, Deerfield Management Company L.P. Series C boosted its position in shares of Phibro Animal Health by 102.4% during the second quarter. Deerfield Management Company L.P. Series C now owns 25,164 shares of the company’s stock valued at $422,000 after buying an additional 12,731 shares during the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.